Aberdeen Wealth Management’s Moderna MRNA Stock Holding History

Aberdeen Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	+1,950	New	+$101K	0.07%	157
2024 Q3	–	Sell	-2,315	Closed	-$275K	–	173
2024 Q2	$275K	Hold	2,315	–	–	0.19%	126
2024 Q1	$247K	Buy	+2,315	New	+$233K	0.14%	137
2023 Q4	–	Sell	-2,315	Closed	-$239K	–	164
2023 Q3	$239K	Hold	2,315	–	–	0.18%	128
2023 Q2	$281K	Hold	2,315	–	–	0.2%	121
2023 Q1	$356K	Hold	2,315	–	–	0.27%	101
2022 Q4	$416K	Hold	2,315	–	–	0.31%	90
2022 Q3	$274K	Hold	2,315	–	–	0.24%	108
2022 Q2	$331K	Hold	2,315	–	–	0.26%	102
2022 Q1	$399K	Hold	2,315	–	–	0.27%	99
2021 Q4	$588K	Hold	2,315	–	–	0.38%	72
2021 Q3	$891K	Hold	2,315	–	–	0.86%	37
2021 Q2	$544K	Sell	2,315 -1,000	-30%	-$179K	0.5%	65
2021 Q1	$434K	Buy	3,315 +175	+6%	+$25.4K	0.35%	91
2020 Q4	$328K	Buy	3,140 +234	+8%	+$23.7K	0.25%	107
2020 Q3	$206K	Buy	+2,906	New	+$203K	0.2%	118

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Aberdeen Wealth Management's MRNA Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Moderna (MRNA) in Q2 2026: 1,950 shares worth $137K. The stake represents 0.07% of the portfolio and ranks #157 among its holdings. This is a return to the name: Aberdeen Wealth Management previously reported a position in MRNA as recently as Q2 2024.

Aberdeen Wealth Management first reported a position in MRNA in Q3 2020 and has held it in 16 quarters since. The position peaked at $891K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Aberdeen Wealth Management held 1,950 shares of Moderna worth $137K as of Q2 2026.
Moderna was a new Aberdeen Wealth Management position in Q2 2026.
Moderna made up 0.07% of Aberdeen Wealth Management's portfolio in Q2 2026, its #157 holding.
Aberdeen Wealth Management first reported a position in Moderna in Q3 2020 and has held it in 16 quarters since.
Aberdeen Wealth Management's Moderna position peaked at $891K in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.